

**AMENDMENTS TO THE CLAIMS**

Please cancel claims 3-11, 14-20, 22-42 and 51-55 are cancelled and amend claims 43-45 and 50, as shown below. A complete listing of the claims, including their current status, is provided below.

**Claims 1-42 (cancelled)**

43. **(Currently amended)** A method for detecting a cancerous cell, said method comprising: detecting a level of a nucleic acid gene product in a test cell ~~obtained from a cell of a subject~~, wherein said gene product is identified by the sequence of SEQ ID NO:3, or complement thereof; and comparing the level of said nucleic acid gene product to a control level of said nucleic acid gene product.

wherein results of said comparing step indicate that the test cell ~~is sample contains~~ a cancerous cell.

44. **(Currently amended)** The method of claim 43, wherein said control level is a level of said nucleic acid gene product in a normal cell, and the presence of a cancerous cell is indicated by detection of a level of said nucleic acid gene product in said test ~~sample~~ cell that is higher than said control level.

45. **(Currently amended)** The method of claim 43, wherein said control level is a level of said nucleic acid gene product in a cancerous cell, and the presence of a cancerous cell is indicated by detection of a level of said nucleic acid gene product in said test ~~sample~~ cell that is similar to said control level.

46. **(Previously presented)** The method of claim 43, wherein said cancerous cell is a cancerous colon cell.

47. **(Previously presented)** The method of claim 43, wherein said nucleic acid gene product is an mRNA or cDNA thereof.

48. **(Previously presented)** The method of claim 43, wherein said detecting step comprises a step of performing a polymerase chain reaction.

49. **(Previously presented)** The method of claim 43, wherein said detecting step comprises a step of performing nucleic acid hybridization.

50. **(Currently amended)** The method of claim 43, wherein said cell sample is a sample of colon cell.

51-55. **(Cancelled)**

56. **(Previously presented)** A method for assessing the tumor burden of a subject, the method comprising:

detecting a level of a nucleic acid product of a gene identified by SEQ ID NO:3 or complement thereof in a test sample from a subject suspected of or having a tumor; and  
comparing said level to a control level of said nucleic acid product;  
wherein results of said comparing step are indicative of the tumor burden in the subject.

57. **(Previously presented)** The method of claim 56, wherein said nucleic acid product is a mRNA or cDNA thereof.

58. **(Previously presented)** The method of claim 56, wherein said test sample is a sample of colon.

59. **(Previously presented)** The method of claim 56, wherein said comparing step indicates that there is an abnormally high level of said nucleic acid gene product.